Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cicapur is a topical healing product developed by Lehning Laboratory, currently positioned within their innovation pipeline. It is designed to facilitate the repair of superficial skin lesions, irritations, and recovery following dermatological procedures. The formulation leverages the regenerative properties of botanical extracts, most notably *Mimosa tenuiflora* (tepezcohuite), which is recognized for its ability to stimulate epidermal regeneration and fibroblast activity, and *Calendula officinalis*, which provides anti-inflammatory and soothing effects. The product is intended to restore the skin barrier, provide a protective environment for wound healing, and reduce the time required for cicatrization. It typically incorporates trace elements such as zinc and copper to maintain a purified skin environment and support enzymatic processes essential for tissue repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cicapur.